Journal of Urgent Care Medicine

Telehealth Providers Face Ever Stronger Headwinds

Industry observers are closely watching for fresh fallout among telehealth providers. For one, the declared end of the semaglutide drug shortage—as per the Food and Drug Administration—sent the stock of Hims & Hers Health, Inc. sliding about 40% within just a few days as investors realized the profits coming from compounding semaglutide for the telehealth company’s patients will quickly dwindle as providers must shift back to the manufacturer’s original brand drug products for weight management …

Semaglutide Compounding Must End, Market Forces Set to Shift

Compounding pharmacies and telehealth companies will ultimately need to stop producing their versions of semaglutide following the resolution of the short-term shortage of the manufacturer’s original brand drug product. Compounding pharmacies were previously allowed to create generic versions of the diabetes and weight loss drug due to supply issues, but with the Food and Drug Administration (FDA) now declaring the shortage over, production and sales must cease by April 22 for pharmacies and May 22 …